QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced results of operations for the first quarter, exceeding goals for net sales and adjusted earnings per share while driving global expansion of its Sample to Insight portfolio of molecular testing solutions covering the continuum from basic research to clinical healthcare.
“Our results for the first quarter have launched QIAGEN into an exciting year of growth for 2018. Our portfolio of Sample to Insight solutions shows good momentum across a broad range of molecular testing needs, and new initiatives offer significant potential for adding to future growth,” said Peer M. Schatz, Chief Executive Officer of QIAGEN N.V.
Please find the full press release here
View source version on businesswire.com: https://www.businesswire.com/news/home/20180502006661/en/
Contacts:
Investor Relations:
John Gilardi, +49 2103 29
11711 and +1 240 686 2222
Vice President Corporate Communications
and Investor Relations
John.gilardi@qiagen.com
or
Dr.
Sarah Fakih, +49 2103 29 11457
Associate Director Investor Relations
Sarah.fakih@qiagen.com
or
Public
Relations:
Dr. Thomas Theuringer, +49 2103 29 11826 and +1 240 686
7425
Senior Director Public Relations and Digital Communications
or
Robert
Reitze, +49 2103 29 11676
Manager Public Relations
pr@qiagen.com
or
www.twitter.com/qiagen
www.facebook.com/QIAGEN
or
Download
the QIAGEN Investor Relations App:
Apple
Android
